# Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-cotransporter-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Paschalis Karakasis,Dimitrios Patoulias,Nikolaos Fragakis,M. Rosa Bernal‐López,Ricardo Gómez‐Huelgas |
| Citations | 17 |
| DOI | 10.1016/j.ejim.2024.07.002 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4400420648 |
| PMID | 38981766 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Dimitrios Patoulias](https://scholariq.org/researchers/dimitrios-patoulias/)
- [Nikolaos Fragakis](https://scholariq.org/researchers/nikolaos-fragakis/)

## Paper journal

- [European Journal of Internal Medicine](https://scholariq.org/journals/european-journal-of-internal-medicine/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.